JP2019511488A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019511488A5 JP2019511488A5 JP2018546817A JP2018546817A JP2019511488A5 JP 2019511488 A5 JP2019511488 A5 JP 2019511488A5 JP 2018546817 A JP2018546817 A JP 2018546817A JP 2018546817 A JP2018546817 A JP 2018546817A JP 2019511488 A5 JP2019511488 A5 JP 2019511488A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- aqueous solution
- allopregnanolone
- hours
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 73
- AURFZBICLPNKBZ-UHFFFAOYSA-N Pregnanolone Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2 AURFZBICLPNKBZ-UHFFFAOYSA-N 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 9
- 201000009916 Postpartum depression Diseases 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims 13
- AURFZBICLPNKBZ-FZCSVUEKSA-N 3beta-hydroxy-5alpha-pregnan-20-one Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 AURFZBICLPNKBZ-FZCSVUEKSA-N 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 12
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 238000001802 infusion Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 8
- 150000003431 steroids Chemical class 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 6
- AURFZBICLPNKBZ-YZRLXODZSA-N 3alpha-hydroxy-5beta-pregnan-20-one Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 AURFZBICLPNKBZ-YZRLXODZSA-N 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 208000019901 Anxiety disease Diseases 0.000 description 4
- 208000024714 major depressive disease Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 208000024732 dysthymic disease Diseases 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- DUHUCHOQIDJXAT-OLVMNOGESA-N 3-hydroxy-(3-α,5-α)-Pregnane-11,20-dione Chemical compound C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1=O DUHUCHOQIDJXAT-OLVMNOGESA-N 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- PGTVWKLGGCQMBR-FLBATMFCSA-N Ganaxolone Chemical compound C([C@@H]1CC2)[C@](C)(O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 PGTVWKLGGCQMBR-FLBATMFCSA-N 0.000 description 2
- 208000002787 Pregnancy Complications Diseases 0.000 description 2
- 206010042458 Suicidal ideation Diseases 0.000 description 2
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- -1 alfadarone Chemical compound 0.000 description 2
- 229960003305 alfaxalone Drugs 0.000 description 2
- AURFZBICLPNKBZ-SYBPFIFISA-N brexanolone Chemical compound C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 AURFZBICLPNKBZ-SYBPFIFISA-N 0.000 description 2
- 229950009652 brexanolone Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000035606 childbirth Effects 0.000 description 2
- 229950007402 eltanolone Drugs 0.000 description 2
- 229950006567 ganaxolone Drugs 0.000 description 2
- 230000000155 isotopic effect Effects 0.000 description 2
- 230000032696 parturition Effects 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 208000012672 seasonal affective disease Diseases 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- KJMHZGDVKPSVNK-LUOXOLFZSA-N CC(C)OC[C@](CC1)([C@H](CC2)C[C@@H]1O)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2C(C[n]1nncn1)=O Chemical compound CC(C)OC[C@](CC1)([C@H](CC2)C[C@@H]1O)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2C(C[n]1nncn1)=O KJMHZGDVKPSVNK-LUOXOLFZSA-N 0.000 description 1
- NKIYALPHXLYICR-HVOJCETBSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(C[n]1nncn1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(C[n]1nncn1)=O NKIYALPHXLYICR-HVOJCETBSA-N 0.000 description 1
- RTZMJBOJCUNCCF-UZNJFETESA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C)O)[C@H]2C(C[n]1ncc(F)c1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C)O)[C@H]2C(C[n]1ncc(F)c1)=O RTZMJBOJCUNCCF-UZNJFETESA-N 0.000 description 1
- GVDKNWHDTOEIQM-LPHGGTRGSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C)O)[C@H]2c1n[o]c(CO)c1 Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C)O)[C@H]2c1n[o]c(CO)c1 GVDKNWHDTOEIQM-LPHGGTRGSA-N 0.000 description 1
- WQANJTALVHXWJH-SFXVUFDXSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2c1n[o]c(CO)c1 Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2c1n[o]c(CO)c1 WQANJTALVHXWJH-SFXVUFDXSA-N 0.000 description 1
- KOXFAJCPBYWCJO-BDVAEDQCSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](COC)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(C[n](nc1cc2)nc1c(F)c2F)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](COC)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(C[n](nc1cc2)nc1c(F)c2F)=O KOXFAJCPBYWCJO-BDVAEDQCSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010065604 Suicidal behaviour Diseases 0.000 description 1
- 208000025748 atypical depressive disease Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- 201000003995 melancholia Diseases 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662305279P | 2016-03-08 | 2016-03-08 | |
| US62/305,279 | 2016-03-08 | ||
| US201662355174P | 2016-06-27 | 2016-06-27 | |
| US62/355,174 | 2016-06-27 | ||
| US201662355669P | 2016-06-28 | 2016-06-28 | |
| US62/355,669 | 2016-06-28 | ||
| US201662360758P | 2016-07-11 | 2016-07-11 | |
| US201662360762P | 2016-07-11 | 2016-07-11 | |
| US62/360,758 | 2016-07-11 | ||
| US62/360,762 | 2016-07-11 | ||
| PCT/US2017/021325 WO2017156103A1 (en) | 2016-03-08 | 2017-03-08 | Neuroactive steroids, compositions, and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021019539A Division JP2021073309A (ja) | 2016-03-08 | 2021-02-10 | 神経刺激性ステロイド、組成物、およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019511488A JP2019511488A (ja) | 2019-04-25 |
| JP2019511488A5 true JP2019511488A5 (enExample) | 2021-02-04 |
| JP6838074B2 JP6838074B2 (ja) | 2021-03-03 |
Family
ID=59789807
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018546817A Active JP6838074B2 (ja) | 2016-03-08 | 2017-03-08 | 神経刺激性ステロイド、組成物、およびその使用 |
| JP2021019539A Pending JP2021073309A (ja) | 2016-03-08 | 2021-02-10 | 神経刺激性ステロイド、組成物、およびその使用 |
| JP2023074398A Pending JP2023093723A (ja) | 2016-03-08 | 2023-04-28 | 神経刺激性ステロイド、組成物、およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021019539A Pending JP2021073309A (ja) | 2016-03-08 | 2021-02-10 | 神経刺激性ステロイド、組成物、およびその使用 |
| JP2023074398A Pending JP2023093723A (ja) | 2016-03-08 | 2023-04-28 | 神経刺激性ステロイド、組成物、およびその使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US20200306265A1 (enExample) |
| EP (1) | EP3426257A4 (enExample) |
| JP (3) | JP6838074B2 (enExample) |
| KR (3) | KR102408399B1 (enExample) |
| CN (2) | CN109414444A (enExample) |
| AU (2) | AU2017229656B2 (enExample) |
| BR (1) | BR112018067998A2 (enExample) |
| CA (2) | CA3158448A1 (enExample) |
| HK (1) | HK1258616A1 (enExample) |
| IL (2) | IL300422B1 (enExample) |
| JO (1) | JOP20170059B1 (enExample) |
| MA (1) | MA43815A (enExample) |
| MX (2) | MX391122B (enExample) |
| NZ (1) | NZ785712A (enExample) |
| PH (2) | PH12018501923B1 (enExample) |
| RU (2) | RU2022102537A (enExample) |
| SG (1) | SG11201807785VA (enExample) |
| TW (2) | TW202400182A (enExample) |
| WO (1) | WO2017156103A1 (enExample) |
| ZA (1) | ZA201805905B (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113234114A (zh) | 2011-10-14 | 2021-08-10 | 萨奇治疗股份有限公司 | 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途 |
| SG10201606063RA (en) | 2012-01-23 | 2016-09-29 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders |
| NZ705410A (en) | 2012-08-21 | 2018-03-23 | Sage Therapeutics Inc | Methods of treating epilepsy or status epilepticus |
| EP2925327B1 (en) | 2012-11-30 | 2024-01-10 | The Regents of The University of California | Allopregnanolone for treating, reducing or mitigating symptoms of post-partum depression |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| SG10201802389SA (en) | 2013-04-17 | 2018-04-27 | Sage Therapeutics Inc | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| PL2986624T3 (pl) | 2013-04-17 | 2020-11-16 | Sage Therapeutics, Inc. | Neuroaktywne steroidy 19-NOR do stosowania w sposobach leczenia |
| AU2014290400B2 (en) | 2013-07-19 | 2019-12-05 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| ES2706180T3 (es) | 2013-08-23 | 2019-03-27 | Sage Therapeutics Inc | Esteroides neuroactivos, composiciones y usos de los mismos |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| SG11201703073UA (en) | 2014-10-16 | 2017-05-30 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
| ME03809B (me) | 2014-10-16 | 2021-04-20 | Sage Therapeutics Inc | KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a |
| SI3224269T1 (sl) | 2014-11-27 | 2020-10-30 | Sage Therapeutics, Inc. | Sestavki in metode za zdravljenje CNS motenj |
| JP6745274B2 (ja) | 2015-01-26 | 2020-08-26 | セージ セラピューティクス， インコーポレイテッド | Ｃｎｓ障害を処置するための組成物および方法 |
| EP3258939B1 (en) | 2015-02-20 | 2022-09-07 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| BR112018067998A2 (pt) | 2016-03-08 | 2019-04-16 | Sage Therapeutics, Inc. | esteróides neuroativos, composições e usos destes |
| EP3481844B1 (en) | 2016-07-11 | 2024-04-17 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| CN116162121A (zh) | 2016-07-11 | 2023-05-26 | 萨奇治疗股份有限公司 | C17、c20和c21取代的神经活性类固醇及其使用方法 |
| AR109393A1 (es) | 2016-08-23 | 2018-11-28 | Sage Therapeutics Inc | Un esteroide 19-nor-c21-pirazolilo c3,3-disustituido cristalino |
| WO2018147791A1 (en) | 2017-02-10 | 2018-08-16 | Asarina Pharma Ab | 3-beta-hydroxy-5-alpha-pregnan-20-one for use in treatment of essential tremor |
| SG11202002085YA (en) * | 2017-09-07 | 2020-04-29 | Sage Therapeutics Inc | Neuroactive steroids and their methods of use |
| US20210228596A1 (en) * | 2017-10-12 | 2021-07-29 | Sage Therapeutics, Inc. | Method of treating cns disorders with neurosteroids and gabaergic compounds |
| EA202091144A1 (ru) * | 2017-11-10 | 2020-09-16 | Маринус Фармасьютикалз, Инк. | Ганаксолон для использования в лечении наследственных эпилептических заболеваний |
| EP4484440A3 (en) | 2017-12-08 | 2025-03-26 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
| CN114085260B (zh) * | 2018-02-11 | 2023-10-20 | 江苏豪森药业集团有限公司 | 甾族类衍生物调节剂、其制备方法和应用 |
| TW202005653A (zh) * | 2018-06-12 | 2020-02-01 | 美商賽吉醫療公司 | 19-去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法 |
| CA3118688A1 (en) * | 2018-11-05 | 2020-05-14 | Ovid Therapeutics Inc. | Use of gaboxadol, ganaxolone and allopregnanolone to treat movement disorders |
| CN109503694A (zh) * | 2018-11-21 | 2019-03-22 | 苏州闻天医药科技有限公司 | 一种新型gabaa受体调节剂及其用途 |
| US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
| US20220089636A1 (en) * | 2019-01-14 | 2022-03-24 | Beijing Xuanyi Pharmasciences Co., Ltd. | Tetrazolone substituted steroids and use thereof |
| US11497754B2 (en) | 2019-02-05 | 2022-11-15 | Washington University | Neurosteroids and enantiomers thereof for the prevention and treatment of neurodegenerative conditions |
| MX2021010744A (es) * | 2019-03-04 | 2022-01-18 | Praxis Prec Medicines Inc | Metodos para el tratamiento de la perimenopausia y la menopausia. |
| AU2020275291A1 (en) | 2019-05-10 | 2021-11-25 | Brii Biosciences, Inc. | Pharmaceutical composition containing brexanolone, ganaxolone, or zuranolone, and use thereof |
| MX2021014515A (es) | 2019-05-31 | 2022-03-22 | Sage Therapeutics Inc | Esteroides neuroactivos y composiciones de estos. |
| WO2021026124A1 (en) | 2019-08-05 | 2021-02-11 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treatment of status epilepticus |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| WO2021113834A1 (en) * | 2019-12-06 | 2021-06-10 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating tuberous sclerosis complex |
| JP2023509798A (ja) * | 2020-01-12 | 2023-03-09 | ブリー バイオサイエンシーズ， インコーポレイテッド | ニューロアクティブステロイド、及びニューロアクティブステロイドを含む医薬組成物 |
| JP2023519241A (ja) | 2020-03-25 | 2023-05-10 | セージ セラピューティクス， インコーポレイテッド | 呼吸器状態の処置のための薬剤の使用 |
| EP4255438A4 (en) * | 2020-12-07 | 2024-10-16 | Marinus Pharmaceuticals, Inc. | USE OF GANAXOLONE IN THE TREATMENT OF AN EPILEPTIC DISORDER |
| CN112516086B (zh) * | 2020-12-08 | 2022-05-20 | 武汉久安药物研究院有限公司 | 注射用布瑞诺龙脂肪乳及其制备方法 |
| WO2022165017A1 (en) * | 2021-01-28 | 2022-08-04 | Sage Therapeutics, Inc. | Use of neuroactive steroids for treatment of sexual dysfunction |
| US20240238314A1 (en) * | 2021-04-12 | 2024-07-18 | Sage Therapeutics, Inc. | Treatment of essential tremor |
| US12208103B1 (en) | 2021-05-07 | 2025-01-28 | Lipocine Inc. | Compositions and methods for treating CNS disorders |
| US11969434B1 (en) | 2022-08-29 | 2024-04-30 | Lipocine Inc. | Oral allopregnanolone compositions and methods of use |
| US11337987B1 (en) * | 2021-05-07 | 2022-05-24 | Lipocine Inc. | Compositions and methods for treating central nervous system disorders |
| MX2024001372A (es) | 2021-07-28 | 2024-02-27 | Sage Therapeutics Inc | Formas cristalinas de un esteroide neuroactivo. |
| WO2023146579A1 (en) * | 2022-01-27 | 2023-08-03 | Belnap Pharmaceuticals, Llc | Methods of treatment using oxytocin |
| WO2023164385A1 (en) * | 2022-02-28 | 2023-08-31 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of gastrointestinal diseases or conditions |
| US20250345345A1 (en) * | 2022-04-26 | 2025-11-13 | Praxis Precision Medicines, Inc. | Methods for the treatment of neurological disorders |
| US12186327B2 (en) | 2022-08-29 | 2025-01-07 | Lipocine Inc. | Oral allopregnanolone compositions and methods of use |
| WO2024059608A1 (en) * | 2022-09-15 | 2024-03-21 | Sage Therapeutics, Inc. | Deuterated neuroactive steroids |
| CN115957332B (zh) * | 2022-11-01 | 2023-10-10 | 北京华睿鼎信科技有限公司 | 透明质酸酶稳定的布瑞诺龙纳米晶及其制备方法与应用 |
| CN120917034A (zh) * | 2023-05-11 | 2025-11-07 | 上海枢境生物科技有限公司 | 甾体类化合物、制备方法及其用途 |
Family Cites Families (138)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3117142A (en) | 1961-03-01 | 1964-01-07 | Roussel Uclaf | Novel preparation of estradiol and estrone |
| US3169134A (en) | 1963-03-21 | 1965-02-09 | Searle & Co | 2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols |
| BE754111A (fr) | 1969-07-29 | 1971-01-29 | Upjohn Co | Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation |
| US3943124A (en) | 1970-12-17 | 1976-03-09 | Gordon Hanley Phillipps | Chemical compounds |
| US3983111A (en) | 1972-05-05 | 1976-09-28 | Glaxo Laboratories Limited | Steroidal anaesthetics of the pregnane and 19-norpregnane series |
| GB1430942A (en) | 1972-05-05 | 1976-04-07 | Glaxo Lab Ltd | 21-substituted 3alpha-hydroxy pregnanes |
| US3865939A (en) | 1973-02-23 | 1975-02-11 | Procter & Gamble | Edible oils having hypocholesterolemic properties |
| US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| GB1570394A (en) | 1976-01-06 | 1980-07-02 | Glaxo Lab Ltd | 11-acyloxy-3-hydroxy steroids |
| US4192871A (en) | 1976-01-06 | 1980-03-11 | Glaxo Laboratories Limited | Chemical compounds |
| GB1581234A (en) | 1976-04-05 | 1980-12-10 | Glaxo Operations Ltd | 11a - amino - 3a - hydroxysteroids |
| SE8600632D0 (sv) | 1986-02-13 | 1986-02-13 | Kabivitrum Ab | Novel pharmaceutical composition |
| US5120723A (en) * | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| US5319115A (en) | 1987-08-25 | 1994-06-07 | Cocensys Inc. | Method for making 3α-hydroxy, 3β-substituted-pregnanes |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5719197A (en) | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| WO1993005786A1 (en) | 1991-09-13 | 1993-04-01 | Cocensys, Inc. | Novel gabaa receptor with steroid binding sites |
| EP0701444B1 (en) | 1993-05-24 | 2010-04-07 | Purdue Pharma Ltd. | Methods and compositions for inducing sleep |
| EP0656365B1 (en) | 1993-12-02 | 1997-04-09 | Akzo Nobel N.V. | Substituted 2beta-morpholinoandrostane derivatives |
| ATE195654T1 (de) | 1994-02-14 | 2000-09-15 | Euro Celtique Sa | Androstane und pregnane zur allosterischen modulation des gaba-rezeptors |
| US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| ES2293638T3 (es) | 1994-03-25 | 2008-03-16 | Isotechnika, Inc. | Mejora de la eficacia de farmacos por deuteracion. |
| JP2002500616A (ja) | 1994-07-21 | 2002-01-08 | ファルマシア・アンド・アップジョン・カンパニー | 神経学的に活性なアミノステロイド |
| DK0808325T3 (da) | 1994-11-23 | 2001-01-29 | Cocensys Inc | Androstan- og pregnanserier til allosterisk modulering af GABA-receptor |
| DE69634039T2 (de) | 1995-06-06 | 2005-12-08 | Euro-Celtique S.A. | Steroidderivate der Androstan- und der Pregnanreihe |
| US6780853B1 (en) | 1995-06-06 | 2004-08-24 | Euro-Celtique S.A. | Neuroactive steroids of the androstane and pregnane series |
| JP4313435B2 (ja) | 1995-07-24 | 2009-08-12 | トラスティーズ オブ ボストン ユニバーシティー | プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制 |
| AU3967297A (en) | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| US7630757B2 (en) | 1997-01-06 | 2009-12-08 | Flint Hills Scientific Llc | System for the prediction, rapid detection, warning, prevention, or control of changes in activity states in the brain of a subject |
| US6245757B1 (en) | 1997-10-03 | 2001-06-12 | Research Corporation Technologies, Inc. | Use of progestins to treat ischemic event |
| AU756001B2 (en) | 1998-03-11 | 2003-01-02 | Umecrine Mood Ab | Epiallopregnanolone in the treatment of CNS disorders |
| US20020198174A1 (en) | 2001-05-07 | 2002-12-26 | Allergan Sales, Inc. | Disinfecting and solubilizing steroid compositions |
| US6376531B1 (en) | 1998-11-13 | 2002-04-23 | Rupert Charles Bell | Method of treatment using deuterium compounds |
| US20030236236A1 (en) | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| DE60001623T2 (de) | 1999-12-03 | 2003-12-18 | Pfizer Products Inc., Groton | Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel |
| US6613308B2 (en) | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
| US20020072509A1 (en) | 2000-10-11 | 2002-06-13 | Stein Donald Gerald | Methods for the treatment of a traumatic central nervous system injury |
| GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| EP1360310A2 (en) | 2001-02-13 | 2003-11-12 | University Of Florida | A bi-directional dual promoter complex with enhanced promoter activity for transgene expression in eukaryotes |
| US20030055026A1 (en) | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
| US6737043B2 (en) | 2001-05-24 | 2004-05-18 | Alexza Molecula Delivery Corporation | Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route |
| US7090830B2 (en) | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
| WO2002094244A2 (en) | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of benzodiazepines through an inhalation route |
| JP2003063965A (ja) | 2001-06-13 | 2003-03-05 | Otsuka Pharmaceut Factory Inc | 注射用シロスタゾール水性製剤 |
| JP2006506445A (ja) | 2002-08-28 | 2006-02-23 | ホリス − イーデン ファーマスーティカルズ、 インコーポレイテッド | 治療処置の方法 |
| US9339508B2 (en) | 2003-01-17 | 2016-05-17 | Mapreg | Use of 3-methoxy-pregnenolone for the preparation of a drug for treating a traumatic brain injury |
| EP1626980A4 (en) | 2003-05-29 | 2007-07-04 | Univ Washington | NEUROACTIVE 13,24-CYCLO-18,21-DINORCHOLANES AND STRUCTURELY RELATED PENTACYCLIC STEROIDS |
| US7816074B2 (en) | 2003-07-31 | 2010-10-19 | The Research Foundation Of State University Of New York | α4 β2 δGABA-A receptors as a strategy for PMS and alcoholism |
| GB0321607D0 (en) | 2003-09-15 | 2003-10-15 | Vectura Ltd | Manufacture of pharmaceutical compositions |
| US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| DE602005026225D1 (de) | 2004-03-12 | 2011-03-24 | Cipla Ltd | Sterilisationsprozess für Steroide |
| WO2005105822A2 (en) | 2004-04-23 | 2005-11-10 | Euro-Celtique S.A. | 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof |
| US20060063707A1 (en) | 2004-09-17 | 2006-03-23 | Lifelike Biomatic, Inc. | Compositions for enhancing memory and methods therefor |
| WO2006037016A2 (en) | 2004-09-27 | 2006-04-06 | The Regents Of The University Of California | Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| EP1807118B8 (en) | 2004-09-29 | 2014-04-23 | Harbor Therapeutics, Inc. | Steroid analogs and characterization and treatment methods |
| AU2006214443C1 (en) | 2005-02-15 | 2011-11-24 | Alkermes Pharma Ireland Limited | Aerosol and injectable formulations of nanoparticulate benzodiazepine |
| EP2030622B1 (en) | 2005-03-24 | 2011-02-23 | Emory University | Indication of dosage of progesterone in the treatment of a traumatic brain injury |
| WO2006110642A2 (en) | 2005-04-07 | 2006-10-19 | Hythiam, Inc. | Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence |
| US20110319386A1 (en) | 2005-08-26 | 2011-12-29 | Braincells Inc. | Neurogenesis by muscarinic receptor modulation |
| KR20120107533A (ko) | 2005-11-28 | 2012-10-02 | 마리누스 파마슈티컬스 | ｇａｎａｘｏｌｏｎｅ 제형, 이의 제조방법 및 용도 |
| US20070287931A1 (en) | 2006-02-14 | 2007-12-13 | Dilorenzo Daniel J | Methods and systems for administering an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders |
| KR20090024140A (ko) * | 2006-05-22 | 2009-03-06 | 반다 파마슈티칼즈, 인코퍼레이티드. | 우울증 질환에 대한 치료 |
| JP2010502722A (ja) | 2006-09-08 | 2010-01-28 | ブレインセルス，インコーポレイティド | ４−アシルアミノピリジン誘導体を含む組み合わせ |
| US20090239942A1 (en) | 2006-09-15 | 2009-09-24 | Cloyd James C | Topiramate Compositions and Methods of Making and Using the Same |
| US20090074677A1 (en) * | 2007-01-08 | 2009-03-19 | Duke University | Neuroactive steroid compositions and methods of use therefor |
| US20090203658A1 (en) | 2007-01-08 | 2009-08-13 | Duke University | Neuroactive steroid compositions and methods of use therefor |
| US7813811B2 (en) | 2007-02-08 | 2010-10-12 | Neuropace, Inc. | Refillable reservoir lead systems |
| DK2139485T3 (da) | 2007-04-11 | 2013-01-21 | Biomarin Pharm Inc | Fremgangsmåder til admistration af tetrahydrobiopterin, associerede sammensætninger, og fremgangsmåder til måling |
| US8530463B2 (en) | 2007-05-07 | 2013-09-10 | Hale Biopharma Ventures Llc | Multimodal particulate formulations |
| WO2008154579A1 (en) | 2007-06-11 | 2008-12-18 | University Of Southern California | Allopregnanolone in a method for enhancing neurological function (alzheimer disease) |
| JP5663303B2 (ja) | 2007-06-15 | 2015-02-04 | リサーチ トライアングル インスティテュート | Ｇａｂａレセプタークロライドイオノフォアの潜在的アロステリック調節特性を有するアンドロスタンステロイドおよびプレグナンステロイド |
| GB0711948D0 (en) | 2007-06-20 | 2007-08-01 | Bionature E A Ltd | Neurosteriod compounds |
| EP2175886A1 (en) | 2007-06-28 | 2010-04-21 | CNSBio Pty Ltd | Combination methods and compositions for treatment of neuropathic pain |
| JP2011507800A (ja) | 2007-12-26 | 2011-03-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 癲癇、精神障害、または感覚器官の障害のためのａｍｐａ受容体アンタゴニスト |
| MX2010006025A (es) | 2008-01-03 | 2010-06-30 | Biomarin Pharm Inc | Analogo de pterina para tratar afeccion sensible a bh4. |
| US20090198145A1 (en) | 2008-02-06 | 2009-08-06 | Chow Harrison | Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep |
| US8729070B2 (en) | 2008-02-20 | 2014-05-20 | Targia Pharmaceuticals | CNS pharmaceutical compositions and methods of use |
| CZ301216B6 (cs) | 2008-07-10 | 2009-12-09 | Ústav organické chemie a biochemie Akademie ved CR, v. v. i. | Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití |
| US8729081B2 (en) | 2008-10-10 | 2014-05-20 | Vm Discovery Inc. | Compositions and methods for treating alcohol use disorders, pain and other diseases |
| CN102300566A (zh) | 2008-11-30 | 2011-12-28 | O·扎查尔 | 血管收缩剂的皮肤应用 |
| EP2376072A1 (en) * | 2008-12-29 | 2011-10-19 | Tartu Ülikool (University Of Tartu) | Arginase inhibitors for the treatment of depression |
| US20110306579A1 (en) | 2009-01-30 | 2011-12-15 | Emory University | Methods of neuroprotection using neuroprotective steroids and a vitamin d |
| US20120142645A1 (en) | 2009-03-17 | 2012-06-07 | Marx Christine E | Neuroactive steroid compositions and methods of use for lowering cholesterol |
| CZ303037B6 (cs) * | 2009-05-28 | 2012-03-07 | Ústav organické chemie a biochemie, Akademie ved CR, v. v. i. | Deriváty pregnanolonu substituované v poloze 3alfa, zpusob jejich výroby a jejich použití |
| US20110152840A1 (en) * | 2009-12-23 | 2011-06-23 | Drugtech Corporation | Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions |
| PL2525798T3 (pl) | 2010-01-21 | 2018-05-30 | Drawbridge Pharmaceuticals Pty Ltd. | Formulacja znieczulająca |
| RU2576506C2 (ru) | 2010-11-03 | 2016-03-10 | Санофи-Авентис Дойчланд Гмбх | Игольчатая канюля, содержащая лекарственный препарат |
| US20130309306A1 (en) | 2010-12-01 | 2013-11-21 | The Regents Of The University Of California | Intrapulmonary benzodiazepine for the treatment and prevention of seizures |
| CZ201181A3 (cs) | 2011-02-15 | 2012-09-12 | Ústav organické chemie a biochemie Akademie ved CR, v.v.i. | Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující |
| US9388210B2 (en) | 2011-02-25 | 2016-07-12 | Washington University | Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| FR2973031B1 (fr) | 2011-03-23 | 2013-11-29 | Univ Strasbourg | Derives de l'allopregnanolone et de l'epiallopregnanolone et leurs utilisations pour traiter un etat neuropathologique |
| US9084797B2 (en) | 2011-05-23 | 2015-07-21 | Besins Healthcare Luxembourg Sarl | Progesterone treatment for improving sleep quality |
| KR20130002292A (ko) | 2011-06-28 | 2013-01-07 | 주식회사 비보존 | 다중 타겟팅의 상승 효과를 유발하는 유효물질의 조합 및 그 용도 |
| EP2736919A4 (en) * | 2011-07-29 | 2015-01-14 | Univ California | NEW 17-BETA-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS |
| HRP20230747T1 (hr) * | 2011-09-08 | 2024-01-05 | Sage Therapeutics, Inc. | Neuroaktivni steroidi, pripravci i njihova uporaba |
| US10478505B2 (en) | 2011-09-23 | 2019-11-19 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| CN113234114A (zh) | 2011-10-14 | 2021-08-10 | 萨奇治疗股份有限公司 | 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途 |
| WO2013079624A1 (en) | 2011-11-29 | 2013-06-06 | Amino Up Chemical Co., Ltd. | Composition comprising vicenin-2 having a beneficial effect on neurological and/or cognitive function |
| SG10201606063RA (en) | 2012-01-23 | 2016-09-29 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders |
| US20150175651A1 (en) | 2012-06-15 | 2015-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2014028398A2 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| NZ705410A (en) | 2012-08-21 | 2018-03-23 | Sage Therapeutics Inc | Methods of treating epilepsy or status epilepticus |
| WO2014058736A1 (en) | 2012-10-08 | 2014-04-17 | Washington University | Neuroactive 19-alkoxy-17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| WO2014071449A1 (en) | 2012-11-09 | 2014-05-15 | Goodchild Investments Pty Ltd | Neuroactive steroids and their use to facilitate neuroprotection |
| EP2925327B1 (en) | 2012-11-30 | 2024-01-10 | The Regents of The University of California | Allopregnanolone for treating, reducing or mitigating symptoms of post-partum depression |
| DK2935307T3 (en) | 2012-12-18 | 2018-07-30 | Univ Washington | NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS USED IN METHODS OF TREATMENT |
| WO2014108808A2 (en) | 2013-01-09 | 2014-07-17 | Henry James Lorne | Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration |
| SG10201802389SA (en) | 2013-04-17 | 2018-04-27 | Sage Therapeutics Inc | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| PL2986624T3 (pl) | 2013-04-17 | 2020-11-16 | Sage Therapeutics, Inc. | Neuroaktywne steroidy 19-NOR do stosowania w sposobach leczenia |
| AU2014290400B2 (en) | 2013-07-19 | 2019-12-05 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| ES2706180T3 (es) | 2013-08-23 | 2019-03-27 | Sage Therapeutics Inc | Esteroides neuroactivos, composiciones y usos de los mismos |
| KR102664412B1 (ko) * | 2014-05-29 | 2024-05-21 | 세이지 테라퓨틱스, 인크. | 신경활성 스테로이드, 조성물, 및 그의 용도 |
| WO2015195962A1 (en) * | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) * | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| CN115381772A (zh) | 2015-02-06 | 2022-11-25 | 马瑞纳斯制药公司 | 静脉内加奈索酮制剂及其用途 |
| GB2541015A (en) | 2015-08-06 | 2017-02-08 | Ge Oil & Gas Uk Ltd | Subsea flying lead |
| CN108697712A (zh) | 2015-10-14 | 2018-10-23 | 加利福尼亚大学董事会 | 增强β细胞复制和/或存活 |
| BR112018067998A2 (pt) | 2016-03-08 | 2019-04-16 | Sage Therapeutics, Inc. | esteróides neuroativos, composições e usos destes |
| EP3586845A1 (en) | 2016-08-11 | 2020-01-01 | Ovid Therapeutics, Inc. | Compositions for treatment of essential tremor |
| US20180050107A1 (en) | 2016-08-16 | 2018-02-22 | Janssen Pharmaceutica Nv | Neurosteroid compositions and methods of use thereof |
| US20180050005A1 (en) | 2016-08-16 | 2018-02-22 | Janssen Pharmaceutica Nv | Concentrated Solution of 17-Hydroxydocosahexaenoic Acid |
| KR102630701B1 (ko) | 2016-09-07 | 2024-01-29 | 글리아, 엘엘씨 | 두개 신경의 약리학적 피부 활성화에 의한 신경변성 질환과 관련된 증상의 치료 |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| WO2018169798A1 (en) | 2017-03-11 | 2018-09-20 | The Regents Of The University Of California | Mitigation of cns disorders by combination therapy using neurosteroids, and ampa blockers |
| KR20190137839A (ko) | 2017-04-18 | 2019-12-11 | 마리누스 파마슈티컬스 인코포레이티드 | 지속 방출 주사용 뉴로스테로이드 제제 |
| US20180338959A1 (en) | 2017-05-24 | 2018-11-29 | Ovid Therapeutics Inc. | Treatment of depressive disorders |
| US11752115B2 (en) | 2017-06-21 | 2023-09-12 | The Board Of Trustees Of The University Of Illinois | PPAR-alpha agonist treatment of neuropsychiatric disorders |
| EP3641779B1 (en) | 2017-06-23 | 2024-02-28 | The Board of Trustees of the University of Illinois | Treatment of neuropsychiatric disorders with neurosteroids and analogues thereof |
| US11992495B2 (en) | 2017-06-23 | 2024-05-28 | The Regents Of The University Of California | Enhancing GABA's ability to modulate immune responses |
| EA202091144A1 (ru) | 2017-11-10 | 2020-09-16 | Маринус Фармасьютикалз, Инк. | Ганаксолон для использования в лечении наследственных эпилептических заболеваний |
| US20190337975A1 (en) | 2018-05-04 | 2019-11-07 | Acerus Pharmaceuticals Corporation | Neurosteroid derivatives and uses thereof |
| EP3876935A4 (en) | 2018-11-08 | 2022-08-17 | Varsona Therapeutics, Inc. | TOPICAL FORMULATIONS OF 5-A REDUCTASE INHIBITORS AND THEIR USES |
| AU2019384157A1 (en) | 2018-11-21 | 2021-06-17 | Certego Therapeutics Inc. | Gaboxadol for reducing risk of suicide and rapid relief of depression |
| US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
| KR20210131305A (ko) | 2018-12-14 | 2021-11-02 | 아세러스 바이오파마 인크. | 테스토스테론의 활성 에스테르 유도체, 조성물 및 그의 용도 |
-
2017
- 2017-03-08 BR BR112018067998-4A patent/BR112018067998A2/pt not_active Application Discontinuation
- 2017-03-08 TW TW112108775A patent/TW202400182A/zh unknown
- 2017-03-08 CA CA3158448A patent/CA3158448A1/en active Pending
- 2017-03-08 KR KR1020187028838A patent/KR102408399B1/ko active Active
- 2017-03-08 CN CN201780027222.4A patent/CN109414444A/zh active Pending
- 2017-03-08 KR KR1020227019157A patent/KR20220084418A/ko not_active Ceased
- 2017-03-08 AU AU2017229656A patent/AU2017229656B2/en active Active
- 2017-03-08 EP EP17763984.6A patent/EP3426257A4/en active Pending
- 2017-03-08 NZ NZ785712A patent/NZ785712A/en unknown
- 2017-03-08 JO JOP/2017/0059A patent/JOP20170059B1/ar active
- 2017-03-08 TW TW106107640A patent/TWI798173B/zh active
- 2017-03-08 CA CA3017172A patent/CA3017172C/en active Active
- 2017-03-08 IL IL300422A patent/IL300422B1/en unknown
- 2017-03-08 RU RU2022102537A patent/RU2022102537A/ru unknown
- 2017-03-08 MA MA043815A patent/MA43815A/fr unknown
- 2017-03-08 RU RU2018135079A patent/RU2766155C2/ru active
- 2017-03-08 SG SG11201807785VA patent/SG11201807785VA/en unknown
- 2017-03-08 MX MX2018010902A patent/MX391122B/es unknown
- 2017-03-08 HK HK19100976.7A patent/HK1258616A1/zh unknown
- 2017-03-08 KR KR1020247035389A patent/KR20240157128A/ko not_active Ceased
- 2017-03-08 US US16/083,339 patent/US20200306265A1/en not_active Abandoned
- 2017-03-08 JP JP2018546817A patent/JP6838074B2/ja active Active
- 2017-03-08 PH PH1/2018/501923A patent/PH12018501923B1/en unknown
- 2017-03-08 CN CN202110912361.3A patent/CN113616661A/zh active Pending
- 2017-03-08 PH PH1/2022/551313A patent/PH12022551313A1/en unknown
- 2017-03-08 WO PCT/US2017/021325 patent/WO2017156103A1/en not_active Ceased
-
2018
- 2018-09-03 ZA ZA2018/05905A patent/ZA201805905B/en unknown
- 2018-09-06 IL IL261658A patent/IL261658B2/en unknown
- 2018-09-07 MX MX2022003896A patent/MX2022003896A/es unknown
-
2019
- 2019-12-18 US US16/718,430 patent/US10940156B2/en active Active
-
2021
- 2021-02-10 JP JP2021019539A patent/JP2021073309A/ja active Pending
- 2021-03-08 US US17/195,129 patent/US11554125B2/en active Active
-
2022
- 2022-12-08 US US18/077,279 patent/US20230355639A1/en not_active Abandoned
- 2022-12-09 AU AU2022283769A patent/AU2022283769B2/en not_active Expired - Fee Related
-
2023
- 2023-04-28 JP JP2023074398A patent/JP2023093723A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019511488A5 (enExample) | ||
| RU2022102537A (ru) | Нейроактивные стероиды, их композиции и применения | |
| Mamas et al. | Premature ovarian failure and dehydroepiandrosterone | |
| JP2017526703A5 (enExample) | ||
| RU2017111816A (ru) | Нейроактивные стероиды, композиции и способы их применения | |
| Lamont et al. | A prospective randomised trial to compare the efficacy and safety of hemabate and syntometrine for the prevention of primary postpartum haemorrhage | |
| JP2017535547A5 (enExample) | ||
| US10799512B2 (en) | Estrogen combination for treatment of multiple sclerosis | |
| JP6746495B2 (ja) | ベンラリツマブを使用して喘息の増悪率を低減する方法 | |
| RU2012117563A (ru) | Режим дозирования модулятора рецептора s1p | |
| RU2017120437A (ru) | Способы лечения хронического синусита с полипами носа путем введения антагониста il-4r | |
| CN114761019A (zh) | 19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法 | |
| Abdieva et al. | CALCIUM INTAKE AND RISK OF FRACTURE DURING THE PREMENOPAUSE PERIODS | |
| CN109999030A (zh) | 牛磺熊去氧胆酸用于治疗神经退行性疾病的用途 | |
| WO2016172672A1 (en) | Method for treating suicidal ideation | |
| JP2019507786A5 (enExample) | ||
| Tomassini et al. | Sex hormones: a role in the control of multiple sclerosis? | |
| JP7326350B2 (ja) | ドライ型ａ．ｍ．ｄ．（加齢黄斑変性）を治療する組成物及び方法 | |
| WO2015160249A2 (en) | Use of enoximone in the treatment of atopic immune-related disorders, in pharmaceutical composition as well as in pharmaceutical preparation | |
| JP2016525530A5 (enExample) | ||
| UA112652C2 (uk) | Фармацевтична композиція для лікування передчасної еякуляції і спосіб лікування передчасної еякуляції | |
| Maksudovna | Indirect influence of hormonal status on the development of ischemic insult and its gender peculiarities | |
| Mushtaq et al. | Effect of dexamethasone on swelling, pain and trismus following third molar surgery | |
| Khanna et al. | Effects of Drugs Used to Treat Infertility on Periodontium and Periodontal Disease | |
| Erensoy et al. | Spontaneous Ejaculation Due to Duloxetine: A Case Report |